CAMP4 Therapeutics (CAMP) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sutro Biopharma (STRO) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 74.5% versus a gain of 16.7%. Sutro Biopharma is the larger company by market cap ($253.2 million vs $225.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | STRO |
|---|---|---|
| Share price | $3.60 | $15.27 |
| Market cap | $225.91M | $253.19M |
| 1-day change | -6.25% | +4.16% |
| YTD return | -37.36% | +26.71% |
| 1-year return | +16.72% | +74.52% |
| 5-year return | — | -92.28% |
| EPS (TTM) | $-2.32 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $43.85 |
| 52-week low | $2.86 | $7.15 |
| Distance from 52-week high | -53.55% | -65.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +193.61% | +209.30% |
| Average volume | 277.90K | 286.74K |
| Shares outstanding | 62.75M | 16.58M |
| Employees | 48 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed CAMP by 57.8 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 128 employees
CAMP vs STRO FAQ
Which is bigger, CAMP4 Therapeutics or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $253.19M compared with $225.91M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or STRO?
STRO returned +74.52% over the past 12 months, compared with +16.72% for CAMP (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Sutro Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for CAMP4 Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Sutro Biopharma.